Meridian
Pharma & biotech signals

Signals

Every pharma-relevant, de-duplicated event surfaced so far, primary source first. Client-scoped signals are never shown here.

Showing 281–300 of 649 signals

AstraZeneca touts Enhertu, Orpathys dual lung cancer wins amid bispecific failure

CompaniesAstraZenecaMSDAssetsvolrustomigKeytrudaEnhertuTagrissoOrpathysDiseasesnon-small cell lung cancerHER2-mutant non-squamous NSCLCEGFRm NSCLC
2 sources — primary and 1 also reporting
Related coverage (4) — shares extracted facts, not the same cluster
Enhertu, Datroway push DXd ADCs across breast cancer treatment landscape
koreabiomed.com·Aug 14, 2026·matches: AstraZeneca · Enhertu
Orpathys plus Tagrisso shows survival benefit in lung cancer
pharmatimes.com·Aug 19, 2026·matches: AstraZeneca · Tagrisso, Orpathys
ASTRAZENECA PLC · ENHERTU IMPROVED PFS IN 1L HER2M LUNG CANCER
sec.gov·Aug 17, 2026·matches: AstraZeneca PLC · ENHERTU
ASTRAZENECA PLC · TAGRISSO+ORPATHYS IMPROVED PFS & OS IN EGFRM LUNG
sec.gov·Aug 17, 2026·matches: AstraZeneca PLC · Tagrisso

Argenx’s stock rises on Phase III autoimmune myositis victory

CompaniesArgenxZai Lab LimitedAssetsVyvgart Hytruloefgartigimod alfa and hyaluronidase-qvfcDiseasesautoimmune myositisimmune-mediated necrotising myopathydermatomyositis

A legacy written in DNA

Diseaseslymphoma

AACR Center for Cancer Clinical Trials Announces First Patient Enrolled in Phase II Clinical Trial for Locally Advanced Gastroesophageal Cancer

CompaniesAACRJazz PharmaceuticalsBeOne Medicines Ltd.Astellas Pharma Inc.Natera, Inc.Roche DiagnosticsAssetszanidatamabtislelizumabzolbetuximabchemotherapy for human epidermal growth factor receptor 2 (HER2)-positive tumorschemotherapy for claudin 18.2 (CLDN18.2)-positive tumorsDiseasesgastroesophageal adenocarcinomalocally advanced gastroesophageal cancer